텔콘RF제약
Shares of Regeneron Pharmaceuticals Inc. slumped 1.2% in morning trading Friday, after the biotechnology company said an independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 recommended that the patient trial be "modified," with the enrollment of some patients place on hold. REGN-COV2 was one of the treatments prescribed to President Trump after he tested positive for COVID-19. Based on a "potential safety signal and an unfavorable risk/benefit profile at this time," the IDMC recommended that further enrollment of patients requiring high-flow oxygen or mechanical...
전문가방송
연관검색종목 03.29 19:30 기준
0/1000 byte